United States of America

Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted versions. Agreements related to the Medical CBRN Defense Consortium (MCDC) whose agreements are executed by Advanced Technology International (ATI) are noted with “(via ATI)”.

KEI has also created a US COVID-19 contract spreadsheet to track metadata of the agreements, as well as to compare the terms contained therein for intellectual property rights, data, and other topics. (Note: At this time, this spreadsheet is being continually updated.)

KEI maintains a separate page of US government contracts concerning needle and syringe production related to the COVID-19 response.

• Advanced Technology International (ATI) – Underlying contract to execute MCDC and COVID-19 contracts on behalf of the federal government.
  • DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016.
  • DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
• Altimmune – therapeutic.
  • DoD-Altimmune Project Approval Letter W81XWH159001. June 17, 2020.
  • DoD-Altimmune Revised Project Approval Letter W81XWH159001. February 3, 2021.
  • DoD-Altimmune Statement of Work W81XWH159001.
• American Blood Center – convalescent plasma.
  • HHS/ASPR/BARDA-American Blood Center Contract 75A50120000094. April 17, 2020.
• ANP Technologies – diagnostics.
  • DoD-ANP Technologies Contract W911QY20D0019. May 29, 2020.
• AstraZeneca – vaccine.
  • HHS/ASPR/BARDA-AstraZeneca Advanced Agreement to Other Transaction Authority Agreement 75A501-20-C-00114. May 20, 2020.
  • HHS/ASPR/BARDA-AstraZeneca Modification of OTA Agreement 75A501-20-C-00114 MODP00001. July 31, 2020.
• AstraZeneca – vaccine.
  • DoD-AstraZeneca Other Transaction Authority Agreement W15QKN2191003. October 28, 2020.
• AstraZeneca – therapeutic.
  • DoD-AstraZeneca Contract W911QY20C0119. September 30, 2020.
• Biofire Defense – diagnostics.
  • DoD-Biofire Defense Supply Order W911QY13D0080-W911QY20F0271. April 24, 2020.
  • DoD-Biofire Defense Supply Order W911QY13D0080-W911QY20F0171. May 23, 2020.
• BCG Federal Corp – COVID-19-related support services.
  • DoD-BCG Federal Corp Contract W911QY20P0198. June 28, 2020.
• Cepheid – test kits.
  • DoD-Cepheid Contract W911QY20P0154. April 27, 2020.
• Corning Incorporated – vaccine manufacturing supplies.
  • DoD-Corning Contract W911NF2030004. June 5, 2020.
• Cue Health – diagnostics manufacturing supplies.
  • DoD-Cue Health Other Transaction Authority Agreement W911NF2190001. October 13, 2020.
• Cue Health – diagnostics.
  • HHS-Cue Health Contract HHSO100201800016C. June 4, 2018.
  • HHS-Cue Health Contract HHSO100201800016C Amendment P00003. May 13, 2020.
• Cytiva (Global Life Sciences Solutions) – vaccine manufacturing supplies.
  • DoD-Cytiva Contract W911NF2130001. October 13, 2020.
• Diomics Corporation – diagnostics. 
  • DoD-Diomics Corporation Project Approval Letter W81XWH159001. August 17, 2020.
  • DoD-Diomics Corporation Revised Project Approval Letter W81XWH159001. February 2, 2021.
  • DoD-Diomics Corporation Statement of Work W81XWH159001.
• Eli Lilly – therapeutic.
  • DoD-Eli Lilly Contract W911QY21C0016. October 27, 2020.
• Emergent Biosolutions – vaccine manufacturing.
  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I. June 15, 2012.
  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I -Task Order 75A50120F33007. May 24, 2020.
• Emory University – therapeutic.
  • DoD (via ATI)–Emory University Technical Direction Letter Other Transaction Authority W15QKN1691002. July 1, 2020.
• Empatica – diagnostics technology.
  • DoD-Empatica Project Approval Letter W81XWH159001. September 10, 2020.
  • DoD-Empatica Statement of Work W81XWH159001.
• Fitbit – diagnostics technology.
  • DoD-Fitbit Project Approval Letter W81XWH1590001. September 23, 2020.
  • DoD-Fitbit Statement of Work W81XWH1590001.
• Fujifilm – therapeutic.
  • DoD (via ATI)–Fujifilm Project Approval Letter 2009COVID19006 under Other Transaction Authority Agreement W81XWH1590001. July 9, 2020.
  • DoD (via ATI)–Fujifilm Revised Project Approval Letter 2009COVID19006 under Other Transaction Authority Agreement W81XWH1590001. December 14, 2020.
  • DoD (via ATI)–Fujifilm Statement of Work 2009COVID19006 under Other Transaction Authority Agreement W81XWH1590001. December 14, 2020.
• Genentech (Roche) -therapeutic.
  • HHS/ASPR/BARDA-Genentech Other Transaction Authority Agreement HHSO100201800036C. September 27, 2018.
  • HHS/ASPR/BARDA-Genentech Modification of OTA Agreement HHSO100201800036C. March 27, 2020.
• GlaxoSmithKline – vaccines.
  • DoD/ASPR/BARDA-GlaxoSmithKline Contract W15QKN20C0048. July 30, 2020.
    • DoD/ASPR/BARDA-GlaxoSmithKline Contract W15QKN20C0048-P00001. July 30, 2020.
    • DoD/ASPR/BARDA-GlaxoSmithKline Contract W15QKN20C0048-P00002. September 16, 2020
• Grifols Therapeutics – convalescent plasma.
  • DoD (via ATI)-Grifols Therapeutics Technical Direction Letter Other Transaction Authority Agreement W15QKN1691002. September 1, 2020.
• Grand River Aseptic Manufacturing (GRAM) – vaccine and therapeutic manufacturing.
  • DoD-Grand River Aseptic Manufacturing (GRAM) Contract W3110Y2OCC086R1033. August 4, 2020.
• Icon – clinical trials.
  • DoD-Icon Other Transaction Authority Agreement W911QY2090007. April 27, 2020.
• Inbios International – diagnostics. 
  • DoD-Inbios International Contract W81XWH20F0253. June 15, 2020.
• Inhalon Biopharma – inhaled prevention/therapeutic.
  • DoD-Inhalon Biopharma Project Approval Letter W81XWH1590001. September 11, 2020.
  • DoD-Inhalon Biopharma Statement of Work W81XWH1590001.
• Inovio Pharmaceuticals – vaccine delivery.
  • DoD-Inovio Pharmaceuticals Contract W911QY20C0084. June 18, 2020. (Version obtained from SEC filings)
  • DoD-Inovio Pharmaceuticals Contract W911QY20C0084. June 18, 2020. (Version obtained via FOIA request)
  • DoD-Inovio Pharmaceuticals Other Transaction Authority Agreement W911QY2090016. June 22, 2020.
• Johnson&Johnson (Janssen) – vaccine.
  • HHS/ASPR/BARDA-Janssen Other Transaction Authority Agreement HHSO100201700018C (Version obtained by FOIA March 31, 2021).
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 6. February 11, 2020.
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 6. February 11, 2020. (Version obtained by FOIA March 31, 2021).
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 7. March 20, 2020.
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 8. March 27, 2020.
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 8. February 11, 2020. (Version obtained by FOIA March 31, 2021).
• Johnson&Johnson (Janssen) – therapeutic.
  • HHS/ASPR/BARDA-Janssen Other Transaction Authority Agreement HHSO100201800012C. September 21, 2018.
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201800012C-Amendment 4. February 14, 2020.
• Johnson&Johnson (Janssen) – vaccine.
  • DoD (via ATI)-Janssen Other Transaction Authority Agreement W15QKN1691002-P00081. August 5, 2020.
• Lumen Bioscience – therapeutic. 
  • DoD-Lumen Bioscience Project Approval Letter W81XWH1590001. July 24, 2020.
  • DoD-Lumen Bioscience Revised Project Approval Letter W81XWH1590001. August 11, 2020.
  • DoD-Lumen Bioscience Revised Project Approval Letter W81XWH1590001. December 9, 2020.
  • DoD-Lumen Bioscience Revised Project Approval Letter W81XWH1590001. February 4, 2021.
  • DoD-Lumen Bioscience Statement of Work W81XWH1590001.
• Maxim – diagnostics.
  • DoD-Maxim Contract W911QY20D0018. May 11, 2020.
• Merck Sharp & Dohme – vaccine.
  • (Note: HHSO100201600031C began as a contract to Bioprotection Systems for an Ebola vaccine, Merck entered into a collaboration agreement with BPS in 2014)
  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C. September 29, 2016.
  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-Attachment 2-Milestones. May 19, 2017.
  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-Attachment 1-Statement of Work. May 19, 2017.
  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-P00001. April 27, 2017.
  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-P00002. September 6, 2017.
  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-P00003. May 23, 2018.
  • HHS/ASPR/BARDA-Merck Sharp & Dohme Contract Amendment HHSO100201600031C-P00004. May 9, 2019.
  • HHS/ASPR/BARDA-Merck Sharp & Dohme Contract Amendment HHSO100201600031C-P00005. April 14, 2020. (Version obtained March 2021 via FOIA lawsuit)
  • HHS/ASPR/BARDA-Merck Sharp & Dohme Contract Amendment HHSO100201600031C-P00005. April 14, 2020.
• Merck Sharp & Dohme – therapeutic.
  • DoD-Merck Sharp & Dohme Other Transaction Authority Agreement W911QY2190001. December 2, 2020.
• Moderna – vaccine.
  • HHS/ASPR/BARDA-Moderna Contract 75A50120C00034. April 16, 2020.
  • HHS/ASPR/BARDA-Moderna Contract 75A50120C00034. April 16, 2020. (Less redacted version obtained via FOIA lawsuit on February 8, 2021)
• Moderna – vaccine manufacturing.
  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained from Moderna SEC filings)
  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained October 29, 2020 from HHS FOIA Reading Room)
  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained November 9, 2020 from HHS FOIA Reading Room)
    • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100-P00001. August 9, 2020.
    • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100-P00002. September 11, 2020.
    • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100-P00003. December 11, 2020.
• Murtech – diagnostics.
  • DoD-Murtech Contract W911QY20D0017. May 11, 2020.
• New Horizons Diagnostics Corp. – diagnostic.
  • DOD (via ATI)-New Horizons Diagnostics Technical Direction Letter Other Transaction Authority Agreement W15QKN1691002. May 26, 2020.
• Novavax – vaccine.
  • DoD-Novavax Contract W911QY20C0077. June 4, 2020.
• Novavax – vaccine.
  • DoD (via ATI)-Novavax Other Transaction Authority Agreement W15QKN1691002. June 25, 2020. (Version obtained via SEC filing)
  • DoD (via ATI)-Novavax Technical Direction Letter W15QKN1691002. July 6, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
  • DoD (via ATI)–Novavax Statement of Work W15QKN1691002. (Version obtained via FOIA lawsuit)
• Ology Bioservices (previously called Nanotherapeutics, Inc.) – vaccine manufacturing.
  • DoD-Ology Bioservices Other Transaction Authority Agreement OTA-W911QY2090003. February 21, 2020.
  • DoD-Ology Bioservices Other Transaction Authority Agreement Appendix OTA-W911QY2090003-Appendix-A-4. March 20, 2020.
  • DoD-Ology Bioservices Contract W911QY2090003-MOD-P00005. March 22, 2020.
• Ology Bioservices (previously called Nanotherapeutics, Inc.) – vaccine manufacturing.
  • DoD-Ology Bioservices Contract W911QY20C0101. August 17, 2020.
• Ophirex – therapeutic.
  • DoD-Ophirex Contract W81XWH20C0066. June 19, 2020.
• Oxford Nanopore Technologies – DNA sequencing.
  • DoD-Oxford Nanopore Technologies Contract W911QX20P0073. April 22, 2020.
• Partner Therapeutics, Inc. – therapeutic.
  • DOD (via ATI)-Partner Therapeutics Technical Direction Letter OTA W15QKN1691002. August 13, 2020.
• Patricio Enterprises – COVID-19 mobile lab staffing.
  • DoD-Patricio Enterprises Contract W911QY18D0251. June 3, 2020.
• Pfizer – vaccine.
  • DoD (via ATI)-Pfizer Technical Direction Letter OTA W15QKN1691002. July 21, 2020.
• Pfizer – vaccines. 
  • DoD-Pfizer Contract W15QKN21C0012. December 22, 2020.
• Philips North America – diagnostics technology.
  • DoD-Philips North America Project Approval Letter W81XWH1590001. August 27, 2020.
  • DoD-Philips North America Revised Project Approval Letter W81XWH1590001. September 23, 2020.
  • DoD-Philips North America Revised Project Approval Letter W81XWH1590001. October 13, 2020.
  • DoD-Philips North America Statement of Work W81XWH1590001.
• Phlow Corporation – therapeutic.
  • HHS/ASPR/BARDA-Phlow Corporation Contract 75A50120000092. May 18, 2020.
• Protein Sciences Corporation (Sanofi) – vaccine.
  • HHS-ASPR/BARDA-Protein Sciences Corp Contract HHSO100201600005I. February 14, 2020.
• Regeneron Pharmaceuticals – therapeutic.
  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C. September 21, 2017.
  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C-MOD(redacted). January 31, 2020.
  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C-MOD0006. (Date redacted).
• Regeneron – therapeutic manufacturing.
  • DoD (via ATI)-Regeneron Other Transaction Authority Agreement W15QKN1691002. July 6, 2020.
  • DoD (via ATI–Regeneron Technical Direction Letter W15QKN1691002. July 6, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
• Rigel Pharmaceuticals – therapeutic.
  • DOD-Rigel Pharmaceuticals Other Transaction Authority Agreement W911QY2190018. January 29, 2021.
• Sanofi – vaccine. 
  • DOD (via ATI)-Sanofi Technical Direction Letter W15QKN1691002. July 30, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
• Sempulse – diagnostics technology. 
  • DoD-Sempulse Project Approval Letter W81XWH1590001. September 23, 2020.
  • DoD-Sempulse Statement of Work W81XWH1590001.
• Sibel – diagnostics technology.
  • DoD-Sibel Project Approval Letter W81XWH1590001. August 27, 2020.
  • DoD-Sibel Statement of Work W81XWH1590001.
• SourceAmerica – face coverings.
  • DoD-SourceAmerica Contract W911QY20C0047. April 17, 2020.
• Tasso – antibody test kits.
  • DoD-Tasso Serology Contract W911QY20P0158. May 1, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
• Ultran Group – treatment device.
  • DOD (via ATI)–Ultran Group Technical Direction Letter Other Transaction Authority Agreement W15QKN1691002. September 16, 2020.
• University of California at San Francisco – diagnostics technology.
  • DoD-UC San Francisco Project Approval Letter W81XWH1590001. August 5, 2020.
  • DoD-UC-San Francisco Statement of Work and Milestone Payment Schedule W81XWH1590001.
• VelocityDX – diagnostics.
  • DoD-VelocityDX Contract W911QY20D0031. August 12, 2020.
• Visby – diagnostics.
  • DoD-Visby Medical Contract W911QY20C0110. September 20, 2020.
• Vyaire Medical, Inc. – ventilators.
  • HHS/ASPR/SNS-Vyaire Medical Contract 75A50120000049. March 31, 2020.
• VxBiosciences – therapeutic.
  • DoD-VxBiosciences Project Approval Letter W81XWH1590001. July 9, 2020.
  • DoD-VxBiosciences Statement of Work W81XWH1590001.
• 98Point6 – COVID-related Smartphone technology.
  • HHS-98Point6 Contract 75A50120C001519. October 9, 2020.

US agreements not concerning COVID-19 research, but tied to related vaccine technologies:

• Moderna – Zika vaccine.
  • HHS/ASPR/BARDA-Moderna Contract HHS0100201600029C. September 1, 2016.

US Government licenses related to COVID-19:

• NIH/NIAID-Geo Vax – vaccine primes/boosters.
  • NIAID-Geo Vax Nonexclusive Patent License Agreement and Biological Materials License. October 22, 2020.
• NIH/NIAID-AbCellera Biologics – vaccines and therapeutics.
  • NIAID-AbCellera Patent License Agreement. May 4, 2020.

Europe

• European Commission-AstraZeneca- vaccine.
  • European Commission-AstraZeneca Advance Purchase Agreement. August 27, 2020.
• European Commission-Curevac – vaccine.
  • European Commission-Curevac Advance Purchase Agreement.
• European Commission-Sanofi Pasteur and GlaxoSmithKline – vaccines.
  • European Commission-Sanofi Pasteur and GlaxoSmithKline Advance Purchase Agreement. September 18, 2020.
• European Investment Bank-BioNTech – financing vaccines.
  • European Investment Bank-BioNTech Finance Contract. June 10, 2020.
• European Investment Bank-Curevac – financing vaccines.
  • European Investment Bank-Curevac Finance Contract. June 27, 2020.

Australia

• Australia-Novavax – vaccine.
  • Australia-Novavax Advanced Purchase Agreement. December 31, 2020.

Brazil

• Fundação Oswaldo Cruz (Fiocruz)-AstraZeneca – vaccine.
  • Fiocruz-AstraZeneca Contract. September 8, 2020.

Canada

• Canada-Novavax – vaccine.
  • Canada-Novavax Advanced Purchase Agreement. January 19, 2021.

China

• Beijing Youfeng-Generex – vaccine.
  • NIVDCP-Beijing Youfeng-Generex Contract YF202011-A. November 13, 2020.

Dominican Republic

• Dominican Republic-Pfizer – vaccine.
  • Dominican Republic-Pfizer Vaccine Term Sheet. January 19, 2021.

Israel

• Israel Ministry of Health-Pfizer – vaccine.
  • Israel MOH-Pfizer Real-World Epidemiological Evidence Collaboration Agreement. January 6, 2021.

United Kingdom

• United Kingdom-Novavax – vaccine.
  • United Kingdom-Novavax Supply Agreement. October 22, 2020.

Inter-company Agreements Concerning COVID-19

• AIM Immuno Tech-Roswell Park Cancer Institute Corporation/Roswell Park Comprehensive Cancer Center – clinical trials.
  • Roswell Park Cancer Institute-AIM Immuno Tech Clinical Trial Agreement. July 6, 2020.
• AIM Immuno Tech-Amarex – clinical trials.
  • AIM Immuno Tech-Amarex Project Work Order Proposal. August 4, 2020.
• Amerimmune-Histogen – therapeutics.
  • Amerimmune-Histogen Collaborative Development and Commercialization Agreement. October 26, 2020.
• Anixa Biosciences-OntoChem – therapeutics.
  • Anixa-OntoChem Collaboration Agreement. April 14, 2020.
• AbCellera Biologics-Eli Lilly and Company – therapeutics.
  • AbCellera-Eli Lilly Research Collaboration and License Agreement. March 11, 2020.
• GlaxoSmithKline-Vir Biotechnologies – vaccines and therapeutics.
  • GlaxoSmithKline-Vir Preliminary Collaboration Agreement. April 5, 2020.
• Hoth Therapetics-George Washington University – smartphone-based direct virus sensing system.
  • Hoth-GWU Sponsored Research Agreement. September 1, 2020.
• Hoth Therapeutics-Voltron Therapeutics – vaccines.
  • Hoth-Voltron Development and Royalty Agreement. March [redacted], 2020.
• Kiromic Biopharma-Molipharma – vaccine, therapeutics, and diagnostics.
  • Kiromic-Molipharma Joint Venture Agreement. April 2, 2020.
• Moderna-Lonza – mRNA vaccines and therapeutics.
  • Moderna-Lonza Global Long Term Agreement. September 4, 2020.
• Nascent Biotech-Manhattan Biosolutions – vaccines and therapeutics.
  • Nascent-Manhattan Research Collaboration Agreement. April 30, 2020.
• Novavax-Serum Institute of India – vaccine.
  • Novavax-Serum Institute Supply and License Agreement. July 30, 2020.
• PharmaCyte Biotech-Hai Kang Life Corporation Limited – diagnostic.
  • PharmaCyte-Hai Kang Life License Agreement. April 2, 2020.
• Pfizer – BioNTech – vaccine.
  • Pfizer-BioNTech Collaboration Agreement. March 17, 2020.